Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with Moffitt Cancer Center. The company was founded in 2012 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-278-8930
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees185
Next Earnings Date2/26/2019 (Estimated)
OptionableOptionable
Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions
What is Atara Biotherapeutics' stock symbol?
Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."
How were Atara Biotherapeutics' earnings last quarter?
Atara Biotherapeutics Inc (NASDAQ:ATRA) posted its earnings results on Tuesday, November, 6th. The biotechnology company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.13) by $0.16. View Atara Biotherapeutics' Earnings History.
When is Atara Biotherapeutics' next earnings date?
What price target have analysts set for ATRA?
9 brokerages have issued twelve-month price targets for Atara Biotherapeutics' stock. Their predictions range from $23.00 to $70.00. On average, they anticipate Atara Biotherapeutics' share price to reach $51.20 in the next year. This suggests a possible upside of 32.7% from the stock's current price. View Analyst Price Targets for Atara Biotherapeutics.
What is the consensus analysts' recommendation for Atara Biotherapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atara Biotherapeutics.
Has Atara Biotherapeutics been receiving favorable news coverage?
Media stories about ATRA stock have been trending positive this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Atara Biotherapeutics earned a news impact score of 2.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Atara Biotherapeutics' key competitors?
Some companies that are related to Atara Biotherapeutics include argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Alector (ALEC), Momenta Pharmaceuticals (MNTA) and Orchard Therapeutics (ORTX).
What other stocks do shareholders of Atara Biotherapeutics own?
Who are Atara Biotherapeutics' key executives?
Atara Biotherapeutics' management team includes the folowing people:
- Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)
- Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)
- Dr. Derrell D. Porter, Sr. VP & Global Commercial Head (Age 48)
- Mr. Utpal Koppikar, Chief Financial Officer
- Dr. Christopher M. Haqq, Exec. VP of R&D & Chief Scientific Officer (Age 53)
Who are Atara Biotherapeutics' major shareholders?
Atara Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.70%), Eagle Asset Management Inc. (3.53%), Northern Trust Corp (1.14%), Geode Capital Management LLC (1.09%), Dimensional Fund Advisors LP (1.04%) and Canada Pension Plan Investment Board (0.42%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, Joe Newell, John Mcgrath, Matthew K Fust, Mitchall G Clark and Utpal Koppikar. View Institutional Ownership Trends for Atara Biotherapeutics.
Which major investors are selling Atara Biotherapeutics stock?
ATRA stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Eagle Asset Management Inc., MetLife Investment Advisors LLC, Squarepoint Ops LLC, Principal Financial Group Inc., New York State Common Retirement Fund, Flinton Capital Management LLC and Northern Trust Corp. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Isaac E Ciechanover, Joe Newell, John Mcgrath, Matthew K Fust and Mitchall G Clark. View Insider Buying and Selling for Atara Biotherapeutics.
Which major investors are buying Atara Biotherapeutics stock?
ATRA stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Canada Pension Plan Investment Board, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Geode Capital Management LLC, Eaton Vance Management, Citigroup Inc., Alps Advisors Inc. and Barclays PLC. View Insider Buying and Selling for Atara Biotherapeutics.
How do I buy shares of Atara Biotherapeutics?
Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atara Biotherapeutics' stock price today?
One share of ATRA stock can currently be purchased for approximately $38.58.
How big of a company is Atara Biotherapeutics?
Atara Biotherapeutics has a market capitalization of $1.76 billion. The biotechnology company earns $-119,490,000.00 in net income (profit) each year or ($4.00) on an earnings per share basis. Atara Biotherapeutics employs 185 workers across the globe.
What is Atara Biotherapeutics' official website?
How can I contact Atara Biotherapeutics?
Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.
MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
